The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a promising targeted therapy combination for patients with relapsed/refractory acute myeloid leukemia (AML), a link between the gut microbiome and therapy-related neutropenic fever, a novel therapeutic target for immunotherapy-related...
The University of Texas MD Anderson Cancer Center and Exscientia plc today announced a strategic collaboration to align the drug discovery...
The University of Texas MD Anderson Cancer Center today announced that Eyal Gottlieb, Ph.D., has been named the institution’s vice president...
Nanotechnology platform enables immune conversion of cancer cells, sensitizing them to immunotherapy
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy. The preclinical findings suggest this adaptable immune conversion approach has the potential for broad application across many cancer types.
The study, published today in Nature Nanotechnology, details the...
ABSTRACTS: 374, 568, 590, 657, 659, 782
The University of Texas MD Anderson Cancer Center’s...
Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco...
In recognition of her trailblazing work uncovering the mechanisms of the p53 tumor suppressor, Guillermina “Gigi” Lozano, Ph.D., chair of...
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe...